Home › Macular Degeneration › Illinois › Chicago
Macular Degeneration clinical trials in Chicago, IL
3 studies for Macular Degeneration are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RecruitingObservational study
- University of Illinois Chicago - UI Health, Chicago
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- University of Illinois at Chicago, Chicago
- Retinal Vitreal Consultants, Chicago
- The University of Chicago, Chicago
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RecruitingPhase 2
- Northwestern Medical Group, Chicago
- The University of Chicago Medicine Duchossois Center for Advanced Medicine, Chicago
About Macular Degeneration
Macular degeneration, or age-related macular degeneration (AMD), is the leading cause of vision loss in older adults. Learn about the types and what might help.
More about Macular Degeneration on MedlinePlus
Macular Degeneration trials in other cities
- Dallas, TX12 studies
- Erie, PA9 studies
- The Woodlands, TX9 studies
- Sacramento, CA7 studies
- Carmel, IN7 studies
- Santa Monica, CA7 studies
- Hagerstown, MD7 studies
- Houston, TX7 studies
- Phoenix, AZ7 studies
- McAllen, TX7 studies
- Cleveland, OH7 studies
- Reno, NV7 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.